Phase I clinical trial of newly developed antigen peptide vaccine for advanced esophageal cancer

Phase I clinical trial of newly developed antigen peptide vaccine for advanced esophageal cancer - Clinical trial of peptide vaccine for esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004662

Enrollment

Registered

2010-12-03

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced esophageal squamous cell carcinoma patietns treated with standart therapy includingn surgery, chemotherapy and radiotherapy, and all these treatments were failed.

Interventions

Peptide Vaccine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Performance status 0-2 Age 20-80 years old WBC 2000<=, <=15000 PLT 75000<= GOT <=150 GPT <=150 T-bil <=2.0 Cr <=2.0 HLA-A2402 Obtained written informed concent

Exclusion criteria

Exclusion criteria: Pregnancy Lactating woman Severe bleeding tendency uncontroled infection concomitant treatment with steroids patients who are judged inappropriate for eligibility by the investigator

Design outcomes

Primary

Measure	Time frame
safety and adverse event of the peptide vaccine	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026